NF2 and kidney neoplasm: Differences in NF2 GA frequencies between the Foundation Medicine (4.9%) and TCGA (2.4%) cohorts could be secondary to selection bias since most tumors being tested in the Foundation Medicine were advanced stage IV kidney tumors in contrast to the limited number of patients with confirmed stage IV disease in TCGA cohort.